RxDoctor Payments Data

Sabeeda Kadavath, MD

Interventional Cardiology · Russellville, ARNPI 1538577333

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $5,427 of the $7,561 with a category attached, or 71.8%. 8 manufacturers reported payments, led by Edwards Lifesciences at 48.5% of the total. Reporting peaked in 2022 at $3,762 and has fallen 98.5% since, to $56 in 2025. That places this record below the midpoint for interventional cardiology clinicians in AR, where the typical reported total is $7,561.

$7,561in general payments, 2019–2025

Across 71 payments — averaging $106.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$4K
  • Medtronic$3K
  • Boston Scientific$268
  • Amgen$115
  • AstraZeneca$103
  • Chiesi USA, Inc.$72
  • plus $53 from 2 others

What the payments were for

  • Travel & lodging$5,42772%
  • Food & beverage$2,13428%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,561 in reported general payments places this provider in the 50th percentile of 89 interventional cardiology providers in Arkansas.

See all interventional cardiology providers in Arkansas

Medicare billing

Part B allowed, 2024
$76,819
Medicare patients
356
Services billed
1,107

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban97$65,426
EntrestoSacubitril/Valsartan78$54,322
JardianceEmpagliflozin54$32,853
BrilintaTicagrelor37$20,281
FarxigaDapagliflozin Propanediol13$12,166
Metoprolol Succinate221$1,938
Atorvastatin Calcium268$1,553
Midodrine Hcl15$980
Dilt-XrDiltiazem Hcl39$793
Ranolazine ErRanolazine20$642
Prasugrel Hcl19$588
Furosemide174$527
ClopidogrelClopidogrel Bisulfate109$405
Isosorbide Mononitrate ErIsosorbide Mononitrate101$388
Lisinopril64$354

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$27$54,32278 claims
AstraZenecaBrilinta, Farxiga$103$32,44750 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 89 interventional cardiology providers in Arkansas.

Other interventional cardiology in Russellville

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →